In this Newsletter:
Join us at SOT 2014
Society of Toxicology ToxExpo
March 23-27, 2014
Title: The Use of Human HepatoPac®, an In Vitro Microliver Platform, for Predictive Toxicology Presenter: Edward LeCluyse, The Hamner Institute 3/25/2014 | 1:30PM - 2:30PM | Room 101A West
Title: Engineering the Microscale Environment Around iPSC-Derived Human Hepatocytes In Vitro Presenter: Salman Khetani, University of Colorado 3/24/2014 | 9:20AM | North Ballroom 120B
- Modified High-content Imaging Micropatterned Hepatocyte Co-Culture Model for Predictive Toxicology Abstract #1973, Poster #245
- Evaluation of the Toxicity Profiles of Selected Bioactivated Compounds in Primary Rat Hepatocytes Cultured in Micropatterned Co-cultures Abstract #1042, Poster #524
- Comparative Metabolism of Eight Model Pharmaceutical Compounds in Rat- and Human- Liver Microsomes, Suspension Hepatocytes, and Micropatterned Co-cultures of Primary Hepatocytes Abstract #1895, Poster #267
Application of HepatoPac® Toward Developing an Integrated Understanding of the Disposition and Metabolism of Faldaprevir.
Presented by: Diane Ramsden, Boehringer-Ingelheim Pharmaceuticals, Inc.
4/9/2014 | 11AM - 12PM
Topics covered include:
- Application of human HepatoPac® to delineate the importance of transporter and enzyme interplay
- Insights into the formation, disposition and elimination of faldaprevir to provide an integrated model of faldaprevir clearance
- Validation of the human HepatoPac® model using rat HepatoPac® to provide an IVIVC
Webinar Associated Peer-Reviewed Publications
- Bridging in vitro and in vivo metabolism and transport of faldaprevir in human using a novel cocultured human hepatocyte system, HepatoPac™. Ramsden, D et al. Drug Metab Dispos March 2014 42:384-39. Read More
- Generating an IVIVC for metabolism and liver enrichment of an HCV drug, faldaprevir, using a rat hepatocyte model (HepatoPac™). Ramsden, D et al. Drug Metab Dispos March 2014 42:384-393. Read More
- Enzyme-Transporter Interplay in the Formation and Clearance of Abundant Metabolites of Faldaprevir Found in Excreta but not in Circulation. Li, Y et al. Drug Metab Dispos March 2014 42:384-393. Read More
Mid-Atlantic User Group Meeting
May 21, 2014
8:30AM - 4:00PM
Philadelphia Marriott West
The Hepregen Mid-Atlantic User Group Meeting will bring together users and prospective users of Hepregen's HepatoPac™ micro-liver platform to discuss practical applications in the fields of drug metabolism and toxicology. Registration is free, but space is limited.
Attendees Will Learn:
- About innovative new HepatoPac applications
- How scientists are using HepatoPac in practical situations
- About the latest validation data
- About recent developments and new pre-clinical species models
Edward LeCluyse; The Hamner Institutes
Mary Grubb; Bristol-Meyers Squibb
Okey Ukairo; Hepregen Corporation
Human Metabolic Stability Kit
Primary hepatocytes in HepatoPac® co-cultures remain metabolically active for up to 35 days allowing for highly accurate metabolic stability studies specializing in slowly metabolized compounds.
- Human HepatoPac® Co-CulturesMaintenance Media
- Application-specific Media and additives
- Instructions for culture maintenance and application-specific protocols
Bring the predictive power of the HepatoPac® micro-liver platform to your lab with these ready-to-use kits.